Crocker, S J <br/><br/>
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.  [electronic resource] 

 -  The European journal of neuroscience  Jul 2001 
 - 391-400 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0953-816X 
<br/><br/><label>Standard No.: </label>10.1046/j.0953-816x.2001.01653.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amphetamine--pharmacology<br/>Amyloid beta-Protein Precursor--drug effects<br/>Animals<br/>Antibodies--pharmacology<br/>Caspase 3<br/>Caspases--drug effects<br/>Cell Survival--drug effects<br/>DNA Fragmentation--drug effects<br/>Disease Models, Animal<br/>Dopamine--metabolism<br/>Fluorescent Dyes--pharmacology<br/>Genetic Vectors--physiology<br/>Immunohistochemistry<br/>Male<br/>Movement Disorders--drug therapy<br/>Neostriatum--metabolism<br/>Nerve Degeneration--drug therapy<br/>Nerve Tissue Proteins--genetics<br/>Neural Pathways--metabolism<br/>Neuronal Apoptosis-Inhibitory Protein<br/>Neurotoxins--pharmacology<br/>Oxidopamine--pharmacology<br/>Parkinsonian Disorders--drug therapy<br/>Rats<br/>Rats, Wistar<br/>Substantia Nigra--metabolism<br/>Sympatholytics--pharmacology